The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Checkpoint inhibitor advances in AML
Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, talks on the utility of checkpoint inhibitors for the treatment of acute myeloid leukemia (AML), specifically the use of nivolumab and azacitidine. Dr Daver also discusses methodology that can be used to predict response to this form of treatment. Additionally, the combination of nivolumab, ipilimumab and azacitidine, as well as the use of CD47 checkpoint inhibitors is discussed. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
